These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

361 related items for PubMed ID: 25395071

  • 1. Circulating semaphorin-4D and plexin-B1 levels in postmenopausal women with low bone mass: the 3-month effect of zoledronic acid, denosumab or teriparatide treatment.
    Anastasilakis AD, Polyzos SA, Makras P, Gkiomisi A, Sakellariou G, Savvidis M, Papatheodorou A, Kokkoris P, Terpos E.
    Expert Opin Ther Targets; 2015 Mar; 19(3):299-306. PubMed ID: 25395071
    [Abstract] [Full Text] [Related]

  • 2. Circulating irisin is associated with osteoporotic fractures in postmenopausal women with low bone mass but is not affected by either teriparatide or denosumab treatment for 3 months.
    Anastasilakis AD, Polyzos SA, Makras P, Gkiomisi A, Bisbinas I, Katsarou A, Filippaios A, Mantzoros CS.
    Osteoporos Int; 2014 May; 25(5):1633-42. PubMed ID: 24599275
    [Abstract] [Full Text] [Related]

  • 3. Comparative effect of zoledronic acid versus denosumab on serum sclerostin and dickkopf-1 levels of naive postmenopausal women with low bone mass: a randomized, head-to-head clinical trial.
    Anastasilakis AD, Polyzos SA, Gkiomisi A, Bisbinas I, Gerou S, Makras P.
    J Clin Endocrinol Metab; 2013 Aug; 98(8):3206-12. PubMed ID: 23788684
    [Abstract] [Full Text] [Related]

  • 4. Semaphorin 4D correlates with increased bone resorption, hypercalcemia, and disease stage in newly diagnosed patients with multiple myeloma.
    Terpos E, Ntanasis-Stathopoulos I, Christoulas D, Bagratuni T, Bakogeorgos M, Gavriatopoulou M, Eleutherakis-Papaiakovou E, Kanellias N, Kastritis E, Dimopoulos MA.
    Blood Cancer J; 2018 May 11; 8(5):42. PubMed ID: 29748532
    [Abstract] [Full Text] [Related]

  • 5. Denosumab in treatment-naïve and pre-treated with zoledronic acid postmenopausal women with low bone mass: Effect on bone mineral density and bone turnover markers.
    Anastasilakis AD, Polyzos SA, Efstathiadou ZA, Savvidis M, Sakellariou GT, Papatheodorou A, Kokkoris P, Makras P.
    Metabolism; 2015 Oct 11; 64(10):1291-7. PubMed ID: 26198440
    [Abstract] [Full Text] [Related]

  • 6. Neutrophil-Derived Semaphorin 4D Induces Inflammatory Cytokine Production of Endothelial Cells via Different Plexin Receptors in Kawasaki Disease.
    Huang J, Wu S, Cao S, Zhu X, Zhang S.
    Biomed Res Int; 2020 Oct 11; 2020():6663291. PubMed ID: 33381571
    [Abstract] [Full Text] [Related]

  • 7. Circulating noggin levels following treatment with denosumab or teriparatide in postmenopausal women with low bone mass.
    Anastasilakis AD, Polyzos SA, Makras P, Rauner M, Sonnleitner L, Hawa G, Tsourdi E, Yavropoulou MP, Missbichler A, Terpos E.
    J Musculoskelet Neuronal Interact; 2019 Sep 01; 19(3):253-257. PubMed ID: 31475931
    [Abstract] [Full Text] [Related]

  • 8. Importance of prompt antiresorptive therapy in postmenopausal women discontinuing teriparatide or denosumab: The Denosumab and Teriparatide Follow-up study (DATA-Follow-up).
    Leder BZ, Tsai JN, Jiang LA, Lee H.
    Bone; 2017 May 01; 98():54-58. PubMed ID: 28286299
    [Abstract] [Full Text] [Related]

  • 9. The effect of teriparatide on serum Dickkopf-1 levels in postmenopausal women with established osteoporosis.
    Anastasilakis AD, Polyzos SA, Avramidis A, Toulis KA, Papatheodorou A, Terpos E.
    Clin Endocrinol (Oxf); 2010 Jun 01; 72(6):752-7. PubMed ID: 19832854
    [Abstract] [Full Text] [Related]

  • 10. Denosumab and teriparatide transitions in postmenopausal osteoporosis (the DATA-Switch study): extension of a randomised controlled trial.
    Leder BZ, Tsai JN, Uihlein AV, Wallace PM, Lee H, Neer RM, Burnett-Bowie SA.
    Lancet; 2015 Sep 19; 386(9999):1147-55. PubMed ID: 26144908
    [Abstract] [Full Text] [Related]

  • 11. Denosumab versus zoledronic acid in patients previously treated with zoledronic acid.
    Anastasilakis AD, Polyzos SA, Gkiomisi A, Saridakis ZG, Digkas D, Bisbinas I, Sakellariou GT, Papatheodorou A, Kokkoris P, Makras P.
    Osteoporos Int; 2015 Oct 19; 26(10):2521-7. PubMed ID: 25990355
    [Abstract] [Full Text] [Related]

  • 12. Circulating periostin levels do not differ between postmenopausal women with normal and low bone mass and are not affected by zoledronic acid treatment.
    Anastasilakis AD, Polyzos SA, Makras P, Savvides M, Sakellariou GT, Gkiomisi A, Papatheodorou A, Terpos E.
    Horm Metab Res; 2014 Feb 19; 46(2):145-9. PubMed ID: 23918682
    [Abstract] [Full Text] [Related]

  • 13. Effects of intravenous zoledronic acid plus subcutaneous teriparatide [rhPTH(1-34)] in postmenopausal osteoporosis.
    Cosman F, Eriksen EF, Recknor C, Miller PD, Guañabens N, Kasperk C, Papanastasiou P, Readie A, Rao H, Gasser JA, Bucci-Rechtweg C, Boonen S.
    J Bone Miner Res; 2011 Mar 19; 26(3):503-11. PubMed ID: 20814967
    [Abstract] [Full Text] [Related]

  • 14. Impact of treatments for postmenopausal osteoporosis (bisphosphonates, parathyroid hormone, strontium ranelate, and denosumab) on bone quality: a systematic review.
    Gallacher SJ, Dixon T.
    Calcif Tissue Int; 2010 Dec 19; 87(6):469-84. PubMed ID: 20872215
    [Abstract] [Full Text] [Related]

  • 15. Changes of Circulating MicroRNAs in Response to Treatment With Teriparatide or Denosumab in Postmenopausal Osteoporosis.
    Anastasilakis AD, Makras P, Pikilidou M, Tournis S, Makris K, Bisbinas I, Tsave O, Yovos JG, Yavropoulou MP.
    J Clin Endocrinol Metab; 2018 Mar 01; 103(3):1206-1213. PubMed ID: 29309589
    [Abstract] [Full Text] [Related]

  • 16. Inhibition of Semaphorin 4D/Plexin-B1 signaling inhibits the subchondral bone loss in early-stage osteoarthritis of the temporomandibular joint.
    Zhang Z, Lu L, Ye T, Yu S, Zhang J, Zhang M, He F, Liu Q, Yang H, Feng J.
    Arch Oral Biol; 2022 Mar 01; 135():105365. PubMed ID: 35151027
    [Abstract] [Full Text] [Related]

  • 17. Switching to Denosumab or Bisphosphonates After Completion of Teriparatide Treatment in Women With Severe Postmenopausal Osteoporosis.
    Kocjan T, Rajic AS, Janez A, Vidmar G, Orehek N, Marc J, Ostanek B.
    Endocr Pract; 2021 Sep 01; 27(9):941-947. PubMed ID: 34111556
    [Abstract] [Full Text] [Related]

  • 18. Circulating activin-A is elevated in postmenopausal women with low bone mass: the three-month effect of zoledronic acid treatment.
    Anastasilakis AD, Polyzos SA, Makras P, Gkiomisi A, Savvides M, Papatheodorou A, Terpos E.
    Osteoporos Int; 2013 Jul 01; 24(7):2127-32. PubMed ID: 23124716
    [Abstract] [Full Text] [Related]

  • 19. Effects of denosumab treatment and discontinuation on bone mineral density and bone turnover markers in postmenopausal women with low bone mass.
    Bone HG, Bolognese MA, Yuen CK, Kendler DL, Miller PD, Yang YC, Grazette L, San Martin J, Gallagher JC.
    J Clin Endocrinol Metab; 2011 Apr 01; 96(4):972-80. PubMed ID: 21289258
    [Abstract] [Full Text] [Related]

  • 20. Plexin-B1 and semaphorin 4D cooperate to promote cutaneous squamous cell carcinoma cell proliferation, migration and invasion.
    Cao J, Zhang C, Chen T, Tian R, Sun S, Yu X, Xiao C, Wang G, Liu Y, Fu M, Li W.
    J Dermatol Sci; 2015 Aug 01; 79(2):127-36. PubMed ID: 26051877
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 19.